DK2336124T3 - Stabilt hydrat af en muscarinreceptorantagonist - Google Patents

Stabilt hydrat af en muscarinreceptorantagonist

Info

Publication number: DK2336124T3
Authority: DK; Denmark
Prior art keywords: receptor antagonist; muscarinic receptor; stable hydrate; hydrate; stable
Prior art date: 2002-03-26

Application number

DK10177716.7T

Other languages

English (en)

Inventor

Peter James Dunn

John George Matthews

Trevor Jack Newbury

Connor Garry O

Original Assignee

Merus Labs Luxco Sarl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-26

Filing date

2003-03-17

Publication date

2012-12-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9933731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2336124(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-03-17 Application filed by Merus Labs Luxco Sarl filed Critical Merus Labs Luxco Sarl

2012-12-17 Application granted granted Critical

2012-12-17 Publication of DK2336124T3 publication Critical patent/DK2336124T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK10177716.7T 2002-03-26 2003-03-17 Stabilt hydrat af en muscarinreceptorantagonist DK2336124T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0207104.1A GB0207104D0 (en)	2002-03-26	2002-03-26	Stable hydrate of a muscarinic receptor antagonist
EP03744716A EP1490357B1 (en)	2002-03-26	2003-03-17	Toluene solvate of darifenacin

Publications (1)

Publication Number	Publication Date
DK2336124T3 true DK2336124T3 (da)	2012-12-17

Family

ID=9933731

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK03744716.6T DK1490357T3 (da)	2002-03-26	2003-03-17	Toluensolvat af darifenacin
DK10177716.7T DK2336124T3 (da)	2002-03-26	2003-03-17	Stabilt hydrat af en muscarinreceptorantagonist

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK03744716.6T DK1490357T3 (da)	2002-03-26	2003-03-17	Toluensolvat af darifenacin

Country Status (22)

Country	Link
US (3)	US6930188B2 (da)
EP (2)	EP2336124B1 (da)
JP (2)	JP2005524678A (da)
KR (4)	KR20100101182A (da)
CN (1)	CN100345840C (da)
AR (1)	AR042608A1 (da)
AT (1)	ATE495169T1 (da)
AU (1)	AU2003209921A1 (da)
BR (2)	BR122018000397B8 (da)
CA (1)	CA2480287C (da)
CY (2)	CY1111200T1 (da)
DE (1)	DE60335711D1 (da)
DK (2)	DK1490357T3 (da)
ES (2)	ES2394067T3 (da)
GB (1)	GB0207104D0 (da)
PA (1)	PA8569701A1 (da)
PT (2)	PT2336124E (da)
SI (2)	SI2336124T1 (da)
SV (1)	SV2003001515A (da)
TW (1)	TW200306816A (da)
UY (1)	UY27735A1 (da)
WO (1)	WO2003080599A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0207104D0 (en) *	2002-03-26	2002-05-08	Pfizer Ltd	Stable hydrate of a muscarinic receptor antagonist
US7244765B2 (en) *	2004-06-25	2007-07-17	Cytokine Pharmasciences, Inc	Guanylhydrazone salts, compositions, processes of making and methods of using
MX2007013064A (es) *	2005-04-24	2008-01-16	Wyeth Corp	Metodo para modular la funcion de la vejiga.
WO2007076159A2 (en) *	2005-12-27	2007-07-05	Teva Pharmaceutical Industries Ltd.	Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
EP2109601A2 (en) *	2007-01-05	2009-10-21	Dr. Reddy's Laboratories Ltd.	Preparation of darifenacin and its salts
CA2675942C (en) *	2007-02-23	2016-04-12	Theravance, Inc.	Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
US20090005309A1 (en) *	2007-05-18	2009-01-01	Auspex Pharmaceuticals, Inc.	Substituted piperidines
WO2009007853A2 (en) *	2007-06-08	2009-01-15	Actavis Group Ptc Ehf	Novel polymorphs of darifenacin free base and its hydrobromide salt
WO2009006413A1 (en) *	2007-06-30	2009-01-08	Auspex Pharmaceuticals, Inc.	Substituted pyrrolidines
WO2009010846A2 (en) *	2007-07-13	2009-01-22	Medichem, S.A.	Amorphous form of darifenacin hydrobromide and processes for the preparation thereof
CZ200845A3 (cs) *	2008-01-28	2009-09-02	Zentiva, A. S.	Zpusob prípravy Darifenacinu
WO2009125426A2 (en) *	2008-02-08	2009-10-15	Neuland Laboratories Ltd	NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE
JP5450387B2 (ja)	2008-04-02	2014-03-26	株式会社カネカ	（ｓ）−３−（１−シアノ−１，１−ジフェニルメチル）−ピロリジンの製造法
WO2010032225A2 (en) *	2008-09-22	2010-03-25	Watson Pharma Private Limited	Process for preparation of darifenacin and intermediates used in the process
EP2236509A1 (en)	2009-04-01	2010-10-06	Ragactives, S.L.	Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
WO2011070419A1 (en)	2009-12-10	2011-06-16	Aurobindo Pharma Limited	An improved process for the preparation of darifenacin hydrobromide
WO2014078568A1 (en)	2012-11-14	2014-05-22	The Johns Hopkins University	Methods and compositions for treating schizophrenia
JP2019502686A (ja) *	2015-12-14	2019-01-31	アイアンウッドファーマシューティカルズインコーポレイテッド	消化管括約筋機能障害の治療へのｓＧＣ刺激薬の使用
JP6965337B2 (ja) *	2016-08-12	2021-11-10	バイエル・クロップサイエンス・アクチェンゲゼルシャフト	置換スチレン誘導体を製造する方法
CN111278503B (zh) *	2017-09-12	2023-12-05	Lts勒曼治疗系统股份公司	离子电渗微针装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8906166D0 (en)	1989-03-17	1989-05-04	Pfizer Ltd	Therapeutic agents
US5233053A (en) *	1989-03-17	1993-08-03	Pfizer Inc.	Pyrrolidine derivatives
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9400600D0 (en)	1994-01-14	1994-03-09	Pfizer Ltd	Treatment of motion seckness
GB9518953D0 (en) *	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
GB9612710D0 (en) *	1996-06-18	1996-08-21	Pfizer Ltd	Method of treatment
KR20010029519A (ko) *	1996-09-19	2001-04-06	이곤 이 버그	요실금 치료 방법
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
GB0207104D0 (en) *	2002-03-26	2002-05-08	Pfizer Ltd	Stable hydrate of a muscarinic receptor antagonist

2002
- 2002-03-26 GB GBGB0207104.1A patent/GB0207104D0/en not_active Ceased
2003
- 2003-03-17 KR KR1020107018853A patent/KR20100101182A/ko not_active Ceased
- 2003-03-17 CA CA2480287A patent/CA2480287C/en not_active Expired - Lifetime
- 2003-03-17 KR KR1020047015243A patent/KR101026283B1/ko not_active Expired - Lifetime
- 2003-03-17 BR BR122018000397A patent/BR122018000397B8/pt not_active IP Right Cessation
- 2003-03-17 WO PCT/IB2003/001043 patent/WO2003080599A1/en not_active Ceased
- 2003-03-17 SI SI200332215T patent/SI2336124T1/sl unknown
- 2003-03-17 SI SI200331973T patent/SI1490357T1/sl unknown
- 2003-03-17 PT PT101777167T patent/PT2336124E/pt unknown
- 2003-03-17 AU AU2003209921A patent/AU2003209921A1/en not_active Abandoned
- 2003-03-17 DE DE60335711T patent/DE60335711D1/de not_active Expired - Lifetime
- 2003-03-17 CN CNB038070847A patent/CN100345840C/zh not_active Expired - Lifetime
- 2003-03-17 KR KR1020117027931A patent/KR101212908B1/ko not_active Expired - Lifetime
- 2003-03-17 PT PT03744716T patent/PT1490357E/pt unknown
- 2003-03-17 EP EP10177716A patent/EP2336124B1/en not_active Expired - Lifetime
- 2003-03-17 AT AT03744716T patent/ATE495169T1/de active
- 2003-03-17 ES ES10177716T patent/ES2394067T3/es not_active Expired - Lifetime
- 2003-03-17 BR BRPI0308706A patent/BRPI0308706B8/pt not_active IP Right Cessation
- 2003-03-17 DK DK03744716.6T patent/DK1490357T3/da active
- 2003-03-17 JP JP2003578353A patent/JP2005524678A/ja not_active Withdrawn
- 2003-03-17 ES ES03744716T patent/ES2358644T3/es not_active Expired - Lifetime
- 2003-03-17 DK DK10177716.7T patent/DK2336124T3/da active
- 2003-03-17 KR KR1020127018787A patent/KR20120098888A/ko not_active Ceased
- 2003-03-17 EP EP03744716A patent/EP1490357B1/en not_active Expired - Lifetime
- 2003-03-20 PA PA20038569701A patent/PA8569701A1/es unknown
- 2003-03-24 AR ARP030101017A patent/AR042608A1/es unknown
- 2003-03-25 US US10/396,887 patent/US6930188B2/en not_active Expired - Lifetime
- 2003-03-25 TW TW092106635A patent/TW200306816A/zh unknown
- 2003-03-25 SV SV2003001515A patent/SV2003001515A/es not_active Application Discontinuation
- 2003-03-25 UY UY27735A patent/UY27735A1/es not_active Application Discontinuation
2005
- 2005-07-13 US US11/180,433 patent/US20050245597A1/en not_active Abandoned
2008
- 2008-03-17 US US12/049,660 patent/US7696357B2/en not_active Expired - Lifetime
2010
- 2010-06-02 JP JP2010126865A patent/JP2010195828A/ja active Pending
2011
- 2011-02-22 CY CY20111100213T patent/CY1111200T1/el unknown
2012
- 2012-11-29 CY CY20121101165T patent/CY1113433T1/el unknown

Also Published As

Publication number	Publication date
EP2336124B1 (en)	2012-08-29
PA8569701A1 (es)	2003-12-10
GB0207104D0 (en)	2002-05-08
ATE495169T1 (de)	2011-01-15
UY27735A1 (es)	2003-10-31
CY1113433T1 (el)	2016-06-22
KR20040093477A (ko)	2004-11-05
PT2336124E (pt)	2012-12-12
ES2358644T3 (es)	2011-05-12
SI1490357T1 (sl)	2011-05-31
JP2010195828A (ja)	2010-09-09
DE60335711D1 (de)	2011-02-24
SI2336124T1 (sl)	2012-12-31
BR0308706A (pt)	2005-01-04
KR101212908B1 (ko)	2012-12-14
AR042608A1 (es)	2005-06-29
HK1080847A1 (zh)	2006-05-04
EP1490357B1 (en)	2011-01-12
US20030191176A1 (en)	2003-10-09
SV2003001515A (es)	2003-12-15
PT1490357E (pt)	2011-03-01
CN1642945A (zh)	2005-07-20
CA2480287C (en)	2011-05-31
KR101026283B1 (ko)	2011-03-31
US20080167367A1 (en)	2008-07-10
EP1490357A1 (en)	2004-12-29
EP2336124A1 (en)	2011-06-22
CY1111200T1 (el)	2015-06-11
WO2003080599A1 (en)	2003-10-02
KR20100101182A (ko)	2010-09-16
BRPI0308706B8 (pt)	2021-05-25
US7696357B2 (en)	2010-04-13
TW200306816A (en)	2003-12-01
DK1490357T3 (da)	2011-04-04
ES2394067T3 (es)	2013-01-16
US20050245597A1 (en)	2005-11-03
CN100345840C (zh)	2007-10-31
JP2005524678A (ja)	2005-08-18
BR122018000397B8 (pt)	2021-07-27
AU2003209921A1 (en)	2003-10-08
CA2480287A1 (en)	2003-10-02
BRPI0308706B1 (pt)	2018-07-10
KR20110130539A (ko)	2011-12-05
US6930188B2 (en)	2005-08-16
KR20120098888A (ko)	2012-09-05
BR122018000397B1 (pt)	2019-07-02
HK1156626A1 (en)	2012-06-15

Publication	Publication Date	Title
NO20051871D0 (no)	2005-04-18	Opioid reseptorantagonister
DK1455756T3 (da)	2008-11-17	Farmaceutisk nanopartikelformig sammensætning af en Tachykinin-receptor-antagonist
DK2065384T3 (da)	2011-05-02	Tricyklisk thrombinreceptor-antagonist
GB0207104D0 (en)	2002-05-08	Stable hydrate of a muscarinic receptor antagonist
DK1638969T3 (da)	2009-01-26	CGRP-receptorantagonister
DE60216229D1 (de)	2007-01-04	Il-8-rezeptorantagonisten
DK2363114T3 (da)	2015-06-22	Opretholdt afgivelse af anti-infektionsmidler
IL158701A0 (en)	2004-05-12	Novel use of nk3 receptor antagonist
EP1498125A4 (en)	2008-08-20	USE OF COMPOUNDS WITH CCR ANTAGONISM
MA28359A1 (fr)	2006-12-01	Antagonistes du recepteur a l'hydroisoindoline tachykinine
IS7780A (is)	2005-03-31	Setið 4-amínó-1-(pýridýlmetýl) píperidín sem múskarínskt viðtaka mótlyf
DE60332816D1 (de)	2010-07-15	Nk1-antagonisten
DE60112051D1 (de)	2005-08-25	Il-8 rezeptor antagonisten
DK1515990T3 (da)	2007-06-11	Antagonister af CXCR3-bindende CXC chemokiner
ATE353215T1 (de)	2007-02-15	Il-8 rezeptor-antagonisten
IS7615A (is)	2004-12-23	Bísýklískar píperidín afleiður sem mótlyf af CCR1flakkboða viðtakanum
ATE352299T1 (de)	2007-02-15	Il-8 rezeptorantagonist
MA25739A1 (fr)	2003-04-01	Antagonistes recepteurs il-8
NO20043799L (no)	2004-09-10	2-oksasolaminer og deres anvendelse som 5-HT2B reseptor antagonister
MA25659A1 (fr)	2002-12-31	Antagonistes recepteurs il-8
NO20033223D0 (no)	2003-07-16	Histamin-reseptor antagonister
ATE370932T1 (de)	2007-09-15	Ccr-3-rezeptorantagonisten vii
DK1440067T3 (da)	2005-04-11	N-formyl-derivater af paroxetin
DK1677779T3 (da)	2009-01-05	Kombination af en antagonist for TP-receptorerne og clopidogrel
ATE320254T1 (de)	2006-04-15	Crf receptor antagonisten